von Schacky Clemens, Harris William S
Medizinische Klinik und Poliklinik Innenstadt, Ludwig Maximilians-Universität München, Ziemssenstrasse 1, D-80336 Munich, Germany.
Cardiovasc Res. 2007 Jan 15;73(2):310-5. doi: 10.1016/j.cardiores.2006.08.019. Epub 2006 Sep 1.
Cardiac societies recommend the intake of 1 g/day of the two omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for cardiovascular disease prevention, treatment after a myocardial infarction, prevention of sudden death, and secondary prevention of cardiovascular disease. These recommendations are based on a body of scientific evidence that encompasses literally thousands of publications. Of four large scale intervention studies three also support the recommendations of these cardiac societies. One methodologically questionable study with a negative result led a Cochrane meta-analysis to a null conclusion. This null conclusion, however, has not swayed the recommendations of the cardiac societies mentioned, and has been refuted with good reason by scientific societies. Based on the scientific evidence just mentioned, we propose a new risk factor to be considered for sudden cardiac death, the omega-3 index. It is measured in red blood cells, and is expressed as a percentage of EPA + DHA of total fatty acids. An omega-3 index of >8% is associated with 90% less risk for sudden cardiac death, as compared to an omega-3 index of <4%. The omega-3 index as a risk factor for sudden cardiac death has striking similarities to LDL as a risk factor for coronary artery disease. Moreover, the omega-3 index reflects the omega-3 fatty acid status of a given individual (analogous to HbA1c reflecting glucose homeostasis). The omega-3 index can therefore be used as a goal for treatment with EPA and DHA. As is the case now for LDL, in the future, the cardiac societies might very well recommend treatment with EPA and DHA to become goal oriented (e.g. an omega-3 index>8%).
心脏学会建议,为预防心血管疾病、心肌梗死后的治疗、预防猝死以及心血管疾病的二级预防,每日摄入1克两种ω-3脂肪酸,即二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)。这些建议基于大量科学证据,这些证据实际上涵盖了数千篇出版物。四项大规模干预研究中有三项也支持这些心脏学会的建议。一项方法上有问题且结果为阴性的研究导致Cochrane荟萃分析得出无效结论。然而,这一无效结论并未动摇上述心脏学会的建议,并且已被其他科学学会合理反驳。基于上述科学证据,我们提出一个在心脏性猝死中需考虑的新风险因素——ω-3指数。它通过红细胞进行测量,并表示为EPA + DHA占总脂肪酸的百分比。与ω-3指数<4%相比,ω-3指数>8%与心脏性猝死风险降低90%相关。ω-3指数作为心脏性猝死的风险因素,与低密度脂蛋白作为冠状动脉疾病的风险因素有着惊人的相似之处。此外,ω-3指数反映了特定个体的ω-3脂肪酸状态(类似于糖化血红蛋白反映葡萄糖稳态)。因此,ω-3指数可作为使用EPA和DHA进行治疗的目标。就像现在对低密度脂蛋白的情况一样,未来,心脏学会很可能会建议以EPA和DHA进行治疗,使其具有目标导向性(例如ω-3指数>8%)。